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Striatum
Reward dysfunction is thought to play a core role in the pathophysiology of major depressive disorder (MDD).
Event-related potential (ERP) and functional magnetic resonance imaging (fMRI) studies have identified reward
processing deficits in MDD, but these methods have yet to be applied together in a single MDD sample. We uti-
lized multimodal neuroimaging evidence to examine reward dysfunction in MDD. Further, we explored how
neurobiological reward dysfunction would map onto subtypes of MDD. The feedback negativity (FN), an ERP
index of reward evaluation,was recorded in 34 unmedicated depressed individuals and 42 never-depressed con-
trols during a laboratory gambling task. Ventral striatal (VS) activation to rewardwas recorded in a separate fMRI
session, using an identical task, among a subgroup of 24depressed individuals and a comparison group of 18non-
depressed controls. FN amplitude was blunted inMDD. This effect was driven by a MDD subgroup characterized
by impaired mood reactivity to positive events, a core feature of melancholic MDD. A similar pattern was ob-
served for VS activation, which was also blunted among the MDD subgroup with impairedmood reactivity. Nei-
ther FN amplitude nor VS activation was related to the full, DSM-defined melancholic or atypical MDD subtypes.
Across the MDD sample, FN amplitude and VS activation were correlated, indicating convergence across
methods. These results indicate that not all MDD is characterized by reward dysfunction, and that there ismean-
ingful heterogeneity in reward processing within MDD. The current study offers neurobiological evidence that
impaired mood reactivity is a key phenotypic distinction for subtyping MDD, and further suggests that the
existing melancholic phenotype may require further refinement.
© 2014 Elsevier Inc. All rights reserved.
Introduction
Major depressive disorder (MDD) ranks among the world's most
common (Kessler and Wang, 2009) and economically burdensome ill-
nesses (Berto et al., 2000; Luppa et al., 2007). A cardinal symptom of
MDD is anhedonia, a pervasive lack of interest or pleasure in normally
enjoyable activities (American Psychiatric Association, 2013), and it
has been suggested that anhedonia may be what distinguishes MDD
from other disorders, including anxiety disorders (Joiner et al., 1996;
Watson et al., 1995a, 1995b) and schizophrenia (Joiner et al., 2003). Re-
cently, there is growing interest in translating findings from basic neu-
roscience to characterize anhedonia with regard to quantitative
deficits in reward processing (Nestler and Carlezon, 2006; Pizzagalli
et al., 2011; Russo and Nestler, 2013). Behavioral studies have linked
MDD with insensitivity to reward contingencies (Henriques and
Davidson, 2000; Pizzagalli et al., 2008), which correlates with self-
reported anhedonia severity (Pizzagalli et al., 2005) and predicts a
poor response to treatment (Vrieze et al., 2012).
Building upon this behavioral data, functional magnetic resonance
imaging (fMRI) studies have begun to shed light on the pathophysiolo-
gy of reward dysfunction inMDD. The striatum is a core region involved
in reward processing (X. Liu et al., 2011), and studies onMDDhave con-
sistently found blunted reward-related activity within this region, in-
cluding in the ventral striatum (VS) (Pizzagalli et al., 2009; Steele
et al., 2007), caudate (Forbes et al., 2006, 2009; Olino et al., 2011;
Smoski et al., 2009), and putamen (Knutson et al., 2008). VS
hypoactivation in particular has been related to anhedonia severity
rather than other symptoms of depression or anxiety (Keedwell et al.,
2005; Wacker et al., 2009); deep brain stimulation of the VS, mean-
while, is effective for treating refractory MDD (Schlaepfer et al., 2008).
Converging evidence has also emerged from electrophysiological re-
search, using event-related potentials (ERPs) to index reward dysfunc-
tion in MDD. ERP studies have focused on the feedback negativity
(FN), a component that is more positive for rewards andmore negative
for non-rewards (Foti et al., 2011b; Gehring and Willoughby, 2002;
Holroyd et al., 2008). The FN is maximal at frontocentral electrodes
300 ms following reward feedback and reflects the early evaluation of
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rewards compared to non-rewards (Foti et al., 2011b; Holroyd et al.,
2008). In non-depressed individuals, FN amplitude has been shown to
correlate with both behavioral and self-reported reward sensitivity
(Bress and Hajcak, 2013). While traditionally thought to be generated
within the anterior cingulate cortex (Gehring and Willoughby, 2002),
it has been proposed that the FNmay also reflect reward-related activity
within the striatum (Foti et al., 2011b). Two recent multimodal studies
have supported this perspective: in an unselected sample in which ERP
and fMRI data were recorded in separate sessions, FN amplitude covar-
ied directly with VS BOLD signal to reward and midbrain gray matter
volume (Carlson et al., 2011, 2014); a subsequent study examining si-
multaneous ERP–fMRI recordings found trial-by-trial associations be-
tween FN amplitude to reward feedback and activation in the VS and
cingulate cortex (Becker et al., 2014).
Notably, blunted FN amplitude is associatedwithMDD symptoms in
both clinical (Liu et al., 2014) andnonclinical samples (Bress et al., 2012;
Foti and Hajcak, 2009), an association which appears to be specific to
symptoms ofMDD and not anxiety (Bress et al., 2013b). Blunted FN am-
plitude may represent a neurobiological mechanism of risk for MDD,
such that it ismore pronounced among individualswith a family history
of MDD (Foti et al., 2011a) and has been shown to prospectively predict
first episode onset of MDD over and above other known risk factors
(Bress et al., 2013a).
Building upon these findings of impaired reward processing inMDD,
we sought to shed further light on the specificity of this dysfunction
using amultimodal neuroimaging approach. Both diminished VS activa-
tion and FN amplitude have been implicated inMDD, yet these neurobi-
ological measures have yet to be considered together. Here, we
integrated ERP and fMRI data on reward dysfunction within a single
MDD sample, testing for convergence across methods (i.e., association
between FN amplitude andVS activation). In a previous report,we dem-
onstrated a link between these hemodynamic and electrophysiological
indices of reward functioning (Carlson et al., 2011); here, we sought
to extend these findings by using multimodal neuroimaging data to
quantify reward dysfunction inMDD. This allowed us to examine the in-
cremental utility in combining fMRI and ERPmeasures to capture group
differences in reward processing.
A further goal was to move beyond diagnostic correlates and le-
verage neural information of reward dysfunction to identify biolog-
ically distinct subgroups within MDD. We tested whether there
would be significant between-subjects variation among depressed
individuals which could allow us to subtype MDD based on the pres-
ence of reward dysfunction. Indeed, evidence of meaningful MDD
subtypes has been inconsistent (Hadzi-Pavlovic and Boyce, 2012).
Although there has long been a distinction between melancholic
and atypical MDD, the validity of these subtypes remains equivocal
with regard to putative etiology, treatment response, and illness
characteristics. From its initial conception, melancholic MDD was
thought to represent an endogenous syndrome (Robertson, 1911).
While some specific biological abnormalities have been identified
in melancholic MDD, notably hypothalamic–pituitary–adrenal axis
dysregulation (Stetler and Miller, 2011), reliable biomarkers with
diagnostic utility are lacking. Melancholic and atypical MDD are
also thought to respond to different types of treatment, yet a study
of 481 patients found that MDD subtype did not predict treatment
response (Bobo et al., 2011). Lastly, a recent study of 818 patients in-
dicated that themelancholic and atypical subtypes – as currently de-
fined – do not separate cleanly using latent class analysis (Lamers
et al., 2010), casting doubt on whether these represent meaningfully
distinct subgroups.
This mixed evidence suggests that the melancholic and atypical
MDD phenotypes may be inadequate and require further refinement.
Rather than startingwith these pre-existing categories and seekingneu-
robiological indicators, it may instead be beneficial to adopt a different
approach: identify novel subgroups based on dysfunction in basic,
well-established processes, irrespective of existing diagnostic
boundaries, and then build outward toward a revised clinical pheno-
type. This approach is articulated within the Research Domain Criteria
Project (RDoC) (Insel et al., 2010), as part of a broader effort to improve
the classification of psychopathology by more fully integrating clinical
and basic science.
Here, we examined whether neural evidence of reward dysfunction
could be used to validate and potentially refine the existingmelancholic
phenotype. As described in the Diagnostic and Statistical Manual of
Mental Disorders (DSM-5) (American Psychiatric Association, 2013),
the primary criteria for melancholic MDD are pervasive anhedonia
and impaired mood reactivity to positive events; atypical MDD is char-
acterized by intact mood reactivity. Based on these definitions, we ex-
pected individuals with melancholic MDD to exhibit profound reward
dysfunction, as evidenced by diminished FN amplitude and VS activa-
tion. Beyond these primary criteria, however, both subtypes are defined
by a number of other, secondary symptoms: melancholic MDD with a
poorer morning mood, early wakening, loss of appetite, agitation, and
inappropriate guilt; atypical MDD with hypersomnia, increased appe-
tite, limb heaviness, and interpersonal sensitivity. Considering this
symptom heterogeneity, we examined whether reward dysfunction
would map more closely onto the full melancholic subtype or instead
to the primary criteria of pervasive anhedonia and impairedmood reac-
tivity. It is noteworthy that, within the DSM-5, mood reactivity to posi-
tive events is the sole illness characteristic that uniquely distinguishes
between the melancholic and atypical subtypes; impaired mood reac-
tivity precludes a diagnosis of atypical MDD, and intact mood reactivity
precludes a diagnosis of melancholic MDD. One possibility, therefore, is
that anhedonia and impaired mood reactivity – the two criteria that are
critical for differentiating the melancholic and atypical subtypes within
the DSM-5 – may represent more powerful “joints” for parsing MDD
into biologically distinct subgroups and elucidating a more specific pro-
file of reward dysfunction in MDD. In this way, it may be possible to re-
fine the relevant phenotypes in a manner that is guided by empirical,
multimodal evidence of neurobiological reward dysfunction.
Methods
Participants
TheMDDgroup consisted of 34 female adults recruited from the com-
munity; only female participants were recruited for the current study
given that prevalence rates of MDD are significantly higher in women
than inmen (Kessler et al., 2003). The inclusion criterionwas a clinical di-
agnosis of unipolar depression (i.e., current MDD and/or dysthymic dis-
order); exclusion criteria were diagnoses of current generalized anxiety
disorder, lifetime obsessive compulsive disorder, lifetime substance
abuse/dependence, more than one other current comorbid Axis I disor-
der, or current prescription of psychiatric medication (past 2 months).
Current comorbid disorders included specific phobia (n= 6), panic dis-
order (2), social phobia (1), and body dysmorphic disorder (1). The
healthy control group consisted of 42 female adults with no diagnosable
lifetime Axis I disorder and no history of neurological illness. Diagnoses
were determined using the Structured Interview for DSM Disorders
(SCID) (First et al., 2001).
ERP data was collected from all 34 depressed and 42 control partic-
ipants. Of these, 24 depressed participants and 6 controls also complet-
ed the fMRI gambling task. To yield an adequate comparison group for
the fMRI task, we included 12 non-depressed participants drawn from
a separate, larger sample who completed the identical fMRI task
(Carlson et al., 2011). These 12 were all female, were comparable in
age to controls and depressed participants (p's N .20), and were free of
any current depressive symptoms (depression score of 0–4 on the 21-
item version of the Depression Anxiety Stress Scale) (Lovibond and
Lovibond, 1995). This yielded final fMRI samples sizes of 24 depressed
patients and 18 non-depressed controls. Participants receivedmonetary
compensation for completing the study. This research protocol was
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approved by the institutional review board at Stony Brook University,
and written informed consent was obtained from all participants.
Symptom measures
Past-week anhedonia and symptom severity was assessed using the
Mood andAnxiety SymptomQuestionnaire (MASQ), a scale designed in
accordance with the tripartite model of depression and anxiety
(Watson et al., 1995a, 1995b). Four subscales were considered: the An-
hedonic Depression and Anxious Arousal subscales capture symptoms
specific to depression and anxiety, respectively; the General Distress—
Depression and General Distress—Anxiety subscales capture symptoms
more common to both disorders. The MASQ has good internal consis-
tency in clinical and non-clinical samples (α N .80), and the disorder-
specific subscales exhibit convergent and discriminant validity
(Watson et al., 1995b). Of interest here was the Anhedonic Depression
subscale, which has been linked to blunted VS activation in a non-
clinical sample (Wacker et al., 2009).
Mood reactivity was coded from the item on the melancholic MDD
module of the SCID for the current depressive episode: “During the
times when you're feeling depressed, if something good happens to
you or if someone tries to cheer you up, do you feel better, at least for
a while?” Responses were coded in a binary manner (intact vs. partial-
ly/fully impaired).
Task
A laboratory gambling task was used to elicit the FN and VS activa-
tion (Carlson et al., 2011; Foti et al., 2011b). The ERP versionwas admin-
istered using Presentation software (Neurobehavioral Systems, Inc.,
Albany, CA). On each trial, participantswere shown a graphic displaying
two doors (occupying 6° of the visual field vertically and 8° horizontal-
ly) and chose one door to open using either the left or right mouse but-
ton. Participants were told that one door contained a prize on each trial.
Following each choice, a feedback stimulus indicatedwhether theywon
or lost money on that trial. A green “↑” indicated a gain of $0.40, and a
red “↓” a loss of $0.20 (each occupying 3° of the visual field vertically
and 1° horizontally). The task consisted of 50 trials (25 wins, 25 losses),
presented pseudorandomly. Stimuli were presented as follows: (i) the
two doors until a response was made, (ii) a fixation mark for 1000 ms,
(iii) a feedback arrow for 2000 ms, (iv) a fixation mark for 1500 ms,
and (v) “Click for the next round” until a response was made. Prior to
the main task, participants completed five practice trials. Halfway
through the task, participants received a break and the amount of
money won at that point was displayed.
The fMRI version of the task was administered using E-Prime
(Psychology Software Tools, Pittsburgh, PA), with identical stimuli
and a similar design. Stimuli were presented as follows: (i) the two
doors for 4000 ms, during which individuals made a response, (ii) a
fixation mark for 500 ms, (iii) a feedback arrow for 1000 ms, (iv) a
blank black screen for a jittered intertrial interval of 1500–14,000
ms (M = 4000 ms). The spacing between events was determined
using the genetic algorithm to optimally sample across the entire he-
modynamic response (Wager and Nichols, 2003). The task consisted
of 60 trials (30 wins, 30 losses) presented pseudorandomly. Partici-
pants first completed two practice trials. Participants were
instructed that if they did not make a response while the doors
were presented, the computer would randomly pick a door for them.
Procedure
The experiment was conducted in a single laboratory session lasting
3 hours: First, the SCID was administered. The ERP and fMRI sessions
were conducted in a random order by an experimenter blind to group
membership. Participants then completed the MASQ. All participants
were paid their task winnings ($5.00 per task) and were compensated
for their time.
ERP data acquisition
The electroencephalogram was recorded using a custom cap
(Cortech Solutions, Wilmington, NC, USA) and the ActiveTwo
Biosemi system (BioSemi, Amsterdam, Netherlands). The signal
was preamplified at the electrode with a gain of one and was digi-
tized at 24-bit resolution with a least significant bit value of
31.25 nV and a sampling rate of 1024 Hz, using a low-pass fifth-
order sinc filter with a −3 dB cutoff of 204.8 Hz. Recordings were
taken from 34 scalp electrodes based on the 10/20 system (including
FCz and Iz), and two mastoid electrodes. The electrooculogram was
recorded from electrodes 1 cm above and below the left eye and
1 cm adjacent to each eye. Electrodes were measured online relative
to a common mode sense electrode forming a monopolar channel.
Brain Vision Analyzer (Brain Products, Munich, Germany) was used
for offline analysis. Data were re-referenced to the mastoid average
and band-pass filtered from 0.01 to 30 Hz. The signal was segmented
from−500 to 1000 ms relative to feedback onset and was corrected
for blinks and eye movements using a regression method (Gratton
et al., 1983). Channels were rejected trial-wise using a semi-
automated procedure, with artifacts identified as: a step of 50 μV be-
tween samples, a 300 μV difference within a trial, or a difference of
less than 0.5 μV within 100-ms intervals. Additional artifacts were
identified visually. ERPs were averaged separately for wins and
losses, and the FN was scored as the mean activity at Fz/FCz from
250 to 350 ms, with a baseline of −200 to 0 ms.
fMRI data acquisition
A 3 Tesla Siemens Trio whole body scanner was used to acquire 242
T2-weighted whole-brain volumes with an EPI sequence sensitive to
BOLD signal, using the following parameters: TR = 2500 ms, TE =
22 ms, flip angle = 83°, matrix dimensions = 96 × 96, FOV =224
× 224mm, slices=40, slice thickness=3.5mm, and gap=0. Standard
preprocessing procedures were performed in SPM8 utilizing default pa-
rameters, including image realignment corrections for headmovements,
slice timing corrections for acquisition order, normalization to standard
2× 2×2mmMontreal Neurological Institute space, and spatial smooth-
ing with a Gaussian full-width-at-half-maximum 8mm filter. An event-
related fixed-effects general linear model (GLM) was created for each
participant. The data was analyzed in an event-related design (i.e.,
stick function), which used the onsets of the win and loss feedback
cues to define our conditions.Win and loss cuesweremodeled separate-
ly, and t-contrasts were created for each participant to examine activa-
tion to wins in comparison to loss (Win N Loss contrast); the lack of an
explicit fixation period precluded the analysis of either win or loss feed-
back alone (e.g., Win N Fixation, Loss N Fixation). Between-subjects ef-
fects were examined by creating a second-level mixed-effects GLM
with win minus loss as a fixed effect and subject as a random effect.
A one-way t-test was calculated to examine reward related activity
across the entire group. Resultantwhole-brain t-mapswere thresholded
at p b .001, uncorrected with a minimum cluster size of 10 voxels. Data
were extracted for each individual, using SPM's principle eigenvariate
extraction, froma 6mmsphere centered on the group-wisemaximal ac-
tivation within the anatomical VS.
Results
Sample characteristics
Demographic and symptom characteristics are presented in Table 1.
The MDD and control groups were well-matched on age, ethnicity, edu-
cation level, and marital status. There was a trend toward a group effect
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on race, with a somewhat higher proportion of Caucasian participants
within the depressed group.1 As expected, self-reported symptoms of
depression and anxiety were more severe among the MDD group.
MDD subtype profiles are presented in Table 2. Eleven individuals
(32.4%) met full DSM criteria for the melancholic subtype, 6 (17.6%)
for atypical, and 17 (50.0%) did notmeet full criteria for either. No signif-
icant group differences in symptoms were observed across DSM sub-
types. Separate from these pre-defined categories, 11 individuals
(32.4%) reported impaired mood reactivity to positive events and 23
(67.6%) reported intact mood reactivity. Impaired mood reactivity was
associated with more severe Anhedonic Depression symptoms.
Reward sensitivity: ERP data
Consistent with previous studies, FN amplitude (Win vs. Loss) was
maximal at 300 ms following feedback onset and at frontocentral elec-
trodes (Fig. 1). The timing and scalp distribution of the FN was compa-
rable across the MDD and control groups. We analyzed FN amplitude
using a mixed-model ANOVA including Feedback as the within-
subjects factor (Win vs. Loss) and Group as the between-subjects factor
(MDD vs. Control). The ANOVA yielded a main effect of Feedback
(F(1,74) = 71.73, p b .001, ηp2 = .49) and an interaction with Group
(F(1,74) = 6.08, p b .05, ηp2 = .08). This interaction indicates that the
modulation of FN amplitude by reward versus non-reward (i.e., Loss
minus Win) was blunted in the MDD group (M = −2.69, SD =
4.39 μV) compared to controls (M = -4.90, SD = 3.43 μV; group
comparison: t(74) = 2.47, p b .05, d = .56); when predicting the FN
to win and loss trials separately (as opposed to the difference score),
the effects of Group were non-significant (p's N .30, d's b .23). Impor-
tantly, within each group the Win vs. Loss contrast was significant
(Control: t(41) = 9.28, p b .001, d = 1.44; MDD: t(33) = 3.57, p =
.001, d =.67). While the FN was blunted in MDD, significant reward-
related neural activity was still present in this group.
Next, the possibility of neurobiologically distinct MDD subgroups
was explored. FN amplitude (Win vs. Loss) was not predicted by DSM
subtype (Table 2). FN amplitude was strongly predicted, however, by
mood reactivity to positive events (Figs. 2a and b). The FNwas substan-
tially blunted among those depressed individuals reporting impaired
mood reactivity (Impaired vs. Intact Mood Reactivity MDD subgroups:
t(32) = 3.96, p b .001, d = 1.46; Impaired Mood Reactivity vs.
Controls: t(51) = 4.96, p b .001, d = 1.66); depressed individuals
with intact mood reactivity and never-depressed controls were indis-
tinguishable in their FN amplitude (t(63) = .54, p = .59, d = .14).
This group difference was driven primarily by a reduced response to re-
ward feedback on win trials (Impaired vs. Intact Mood Reactivity MDD
subgroups: t(32)= 2.74, p b .05, d= .99; ImpairedMood Reactivity vs.
Controls: t(51) = 2.77, p b .01, d= .91), rather than to monetary loss
(p's N .30, d's b .38). The within-subjects contrast (Win vs. Loss)
revealed robust reward-related neural activity within the intact mood
reactivity MDD subgroup (t(22) = 5.71, p b .001, d = 1.21), but
not within the impaired mood reactivity MDD subgroup (t(10) = .84,
p= .42, d= .30).
Across the full MDD group, no significant associations were ob-
served between blunted FN amplitude and anhedonia, symptom sever-
ity, or age of onset (r's from .17 to -.32, all p's N .05). Next, we examined
the unique impact of illness characteristics on FN amplitude usingmul-
tiple linear regression;mood reactivity status and scores on the two de-
pression subscales of the MASQ (Anhedonic Depression and General
Distress—Depression) were entered as simultaneous predictors. Con-
trolling for anhedonia and symptom severity in this manner, the link
between impairedmood reactivity and blunted FN amplitude remained
significant (rpartial = .53, p b .01); the unique effects of the two symp-
tom subscales were non-significant (both p's N .15).
Reward sensitivity: fMRI data
Reward-related activity was isolated using a whole brain analysis for
the Win N Loss contrast. This revealed robust bilateral activation in the
VS across the full sample (Fig. 2c), with a global maximum in the right
VS (k = 1160, t(41) = 7.07, peak at MNI: 10, 10, −2).2 To capture
between-subjects variation in VS activity, the modulating effects of
MDD and mood reactivity were examined. Unlike the FN, there was no
main effect of Group (MDD vs. Non-Depressed) on VS activity (t(40) =
.84, p= .41, d= .26). As with FN amplitude, however, VS activity was
blunted among those depressed individualswith impairedmood reactiv-
ity compared to the rest of the sample (Fig. 2d; t(40)= 2.29, p b .05, d=
.84); depressed individuals with intact mood reactivity were indistin-
guishable from the non-depressed comparison group in terms of VS acti-
vation (t(30) = .25, p = .80, d = .09). The within-subjects contrast
revealed robust reward-related VS activation in the non-depressed com-
parison group (t(17)= 4.76, p b .001) and in theMDD subgroupwith in-
tact mood reactivity (t(13) = 4.73, p b .001), but not within the MDD
subgroup with impaired mood reactivity (t(9) = 1.28, p= .23). This ef-
fect ofmood reactivitywas not captured by DSM subtype, whichwas un-
related to VS activation within the full depressed group (Table 2).3
1 Race did notmoderate the current results: across the full sample, FN amplitude andVS
activation (Win vs. Loss) were comparable across Race category (both p's N .25). Within
the MDD group, the effect of impaired mood reactivity on both measures of reward-
related neural activity remained significant after adjusting for Race (FN: F(1,29) = 9.10,
p b .01; VS: F(1,20) = 5.56, p b .05).
2 Although data were not corrected for multiple comparisons during whole-brain anal-
yses, an examination of cluster-wise and peak-wise corrections revealed that both the
cluster (p b .001 FWE-corrected) and peak-voxel (p b .01 FWE-corrected) passed correc-
tion for multiple comparisons.
3 Due to the different healthy comparison groups used for the ERP and fMRI analyses, we
also replicated these between-groups comparisons when considering only those partici-
pants with full data (MDD: n = 24; Controls: n = 6). An identical pattern of results
emerged: the FN (Win vs. Loss) was blunted among the MDD group compared to Controls
(F(1,28)= 4.68, p b .05), and this effect was driven specifically by theMDD subgroupwith
impairedmood reactivity (ImpairedMood Reactivity vs. Control: t(14)= 3.97, p b .01; Im-
paired vs. Intact Mood Reactivity: t(22)= 2.83, p b .05; Intact Mood Reactivity vs. Control:
t(18) = 1.29, p= .21). Similarly, the effect of mood reactivity on VS activation remained
significant, with the MDD subgroup with impaired mood reactivity exhibiting blunted VS
activation compared to the rest of the sample (t(28) = 2.10, p b .05); the Intact Mood Re-
activity subgroup and Controls did not differ from one another (t(18) = .50, p= .62).
Table 1
Demographic and symptom characteristics of sample.
Depressed
(n = 34)
Control
(n = 42)
Group comparison
N % n % Fisher's exact test (p)
Ethnicity
Hispanic/Latino 2 5.9 3 8.6 1.00
Other 32 94.1 32 91.4
Race
Caucasian 24 72.7 17 50.0 .08⁎
Other 9 27.3 17 50.0
Education
Part college or less 21 61.8 30 71.4 .46
College degree 13 38.2 12 28.6
Marital status
Ever married 8 23.5 7 17.1 .57
Never married 26 76.5 34 82.9
M SD M SD t(df)
Age 26.00 8.89 23.79 7.12 1.21(74)
Symptoms
Anhedonic depression 64.36 12.74 40.00 11.10 8.35(65)⁎⁎
General distress, depression 38.09 11.60 19.09 5.72 8.51(65)⁎⁎
Anxious arousal 30.36 10.90 21.00 4.59 4.61(65)⁎⁎
General distress, anxiety 25.21 8.65 16.50 4.67 5.15(65)⁎⁎
Note: Symptoms are subscales from the Mood and Anxiety Symptom Questionnaire.
⁎ p b .10
⁎⁎ p b .001.
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Across the full MDD group, no significant associations were ob-
served between reduced VS activation and anhedonia, symptom sever-
ity, or age of onset (r's from .02 to− .40, p's N .05). Next, we examined
the unique impact of illness characteristics on VS activation using mul-
tiple linear regression; mood reactivity and scores on the two depres-
sion subscales of the MASQ (Anhedonic Depression and General
Distress—Depression) were entered as simultaneous predictors. Con-
trolling for anhedonia and symptom severity, the link between im-
paired mood reactivity and reduced VS activation was no longer
significant (rpartial = .28, p= .21); the effects of the two symptom sub-
scales were also non-significant (both p's N .30).
Convergence across ERP and fMRI data
Among depressed individuals, there was convergence across elec-
trophysiological and hemodynamic measures of reward sensitivity
(Fig. 3), with a significant correlation between FN amplitude and VS ac-
tivation (r = .39, pone-tailed b .05). This association was driven by the
MDD subgroup with intact mood reactivity (r = .49, pone-tailed b .05),
and was not apparent within the MDD subgroup with impaired mood
reactivity (r= -.16, pone-tailed = .33). The comparison of these correla-
tion coefficients approached significance (z= 1.44, pone-tailed = .07).
To examine for unique effects of FN amplitude and VS activation, we
entered each as simultaneous predictors using binary logistic regres-
sion. When predicting Group (MDD vs. Non-Depressed), an effect was
observed for FN amplitude (OR = .68, p b .01, 95% CI = .52–.88) but
not VS activation (OR = .95, p = .93, 95% CI = .29–3.1). When
predicting Mood Reactivity, an effect was again observed for FN
amplitude (OR = .64, p b .01, 95% CI = .47–.87) but not VS activation
(OR = .31, p= .18, 95% CI = .06–1.7).
Discussion
The current study sheds new light on the nature of reward dysfunc-
tion in MDD in three ways. First, building upon past ERP research in
non-clinical samples (Bress et al., 2012, 2013b; Foti and Hajcak, 2009)
and replicating a recent report from a clinical sample (W. H. Liu et al.,
2014), MDD was associated with reduced reward-related neural
activity, as indicated by FN amplitude. Second, we found converging ev-
idence across ERP and fMRI measures, such that FN amplitude and VS
activation to reward were correlated within the MDD group. This repli-
cates and extends the findings of a previous study conducted in an un-
selected sample (Carlson et al., 2011) and is the first application of a
multimodal neuroimaging approach for characterizing reward insensi-
tivity in MDD. Third, moving beyond standard diagnostic comparisons,
we found that blunted FN amplitude was driven specifically by an
MDD subgroup characterized by impaired mood reactivity to positive
events; among the MDD subgroup with intact mood reactivity, FN am-
plitude was unaffected and indistinguishable from never-depressed
controls. This effect of mood reactivity was independent of self-
reported anhedonia, which did not significantly predict FN amplitude.
Similarly, and demonstrating further convergence across ERP/fMRI
measures, VS activation to rewards was blunted specifically among de-
pressed individualswith impairedmood reactivity. These novel findings
go beyond diagnostic differences in reward functioning related toMDD,
linking hyposensitivity to reward to a more specific phenotype. In con-
trast, no effects were observed for the full, DSM-defined melancholic
and atypical MDD subtypes, which did not adequately map onto neural
data of reward dysfunction.
Mood reactivitywas an effective “joint” for dividing theMDDsample
into two distinct subgroups: one characterized by reward dysfunction,
and one by normal reward processing. This was not the case for the
existing DSM subtypes of melancholic and atypical MDD, which did
not predict impairment in either FN amplitude or VS activation. Within
the DSM-5, impaired versus intact mood reactivity is recognized as a
key illness characteristic for subtyping MDD (American Psychiatric As-
sociation, 2013). The current results lend biological support for this fun-
damental distinction, across both ERP and fMRI measures. Mood
reactivity alone, however, is insufficient to subtypeMDDwithin the cur-
rent diagnostic framework, as a number of other, secondary symptoms
must also be present. Considered in light of the current results, it is pos-
sible that the melancholic phenotype – as currently defined – is inade-
quate, which may explain the inconsistent support for melancholia as
a distinct MDD subtype (Hadzi-Pavlovic and Boyce, 2012). The existing
phenotype consists of a heterogeneous cluster of symptoms, but it is
specifically the primary criterion of impaired mood reactivity which
Table 2
Symptom severity and reward sensitivity by depression subtype.
Mood reactivity to positive events Impaired (n = 11) Intact (n = 23) Group comparison
M SD M SD F(df)
Neural response to reward
Feedback negativity -.90 3.56 4.41 3.70 15.68(1,32)⁎⁎
Ventral striatum .24 .60 .80 .63 4.66(1,22)⁎
Symptoms
Anhedonic depression 71.70 10.40 61.17 12.52 5.41(1,31)⁎
General distress, depression 42.40 8.14 36.22 12.59 2.02(1,31)
Anxious arousal 32.40 8.87 29.48 11.74 .49(1,31)
General distress, anxiety 28.90 8.65 23.61 8.33 2.75(1,31)
Age of depression onset 14.56 3.32 17.50 6.00 1.90(1,29)
DSM Subtype Melancholic (n = 11) Atypical (n = 6) Neither (n = 17) Group comparison
M SD M SD M SD F(df)
Neural response to reward
Feedback negativity 3.72 5.14 3.59 3.28 1.71 4.23 .84(2,31)
Ventral striatum .59 .69 .68 .12 .52 .79 .08(2,21)
Symptoms
Anhedonic depression 61.40 11.70 66.17 10.50 65.47 14.33 .38(2,30)
General distress, depression 36.50 10.72 34.33 16.37 40.35 10.55 .71(2,30)
Anxious arousal 31.90 8.36 26.67 11.22 30.76 12.34 .44(2,30)
General distress, anxiety 26.10 8.29 19.00 5.37 26.88 9.17 2.04(2,30)
Age of depression onset 17.40 5.60 15.80 5.68 16.44 5.65 .16(2,28)
Note: Symptoms are subscales from the Mood and Anxiety Symptom Questionnaire. Amplitude of the feedback negativity (Win vs. Loss) was converted to a positive number, such that
larger numbers indicate greater reward-related neural activity.
⁎ p b .05.
⁎⁎ p b .001.
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appears to be linked to abnormal reward processing. Building outward
from these findings, it may be possible to continue to iteratively refine
more specific MDD phenotypes in a manner that is directly grounded
in basic neuroscience (Insel et al., 2010).
Depressed individuals with impaired mood reactivity also reported
more severe anhedonia, but only mood reactivity captured variation in
FN amplitude and VS activation. Anhedonia was measured using the An-
hedonic Depression subscale of the MASQ, which combines numerous
facets of hedonic capacity, including anticipatory and consummatory
pleasure (Watson et al., 1995a, 1995b). As such, this general measure of
anhedonia may be conflating subjective experiences that map onto the
distinct reward components, such as “liking” and “wanting” (Berridge
et al., 2009).Mood reactivity to positive events, by contrast, is amore nar-
rowly defined construct: a persistently low, nonreactive mood even in
the face of positive events. This construct relatesmore directly to “liking,”
particularly the RDoC construct of Initial Responsiveness to Reward At-
tainment. The current pattern of results indicates a specific link between
a facet of reward dysfunction (i.e., “liking”) and the key illness character-
istic ofmood reactivity, rather than amore global deficit in positive affect.
Other relevant reward facets, as outlined by RDoC, include Approach
Motivation (i.e., “wanting”) and Reward Learning—both of which have
been related to MDD. For example, there is evidence that while viewing
pleasurable stimuli, MDD patients exhibit a deficit in subjective antici-
patory but not consummatory pleasure (Sherdell et al., 2012). Other
work has linkedMDD to a behavioral deficit in the acquisition of reward
contingencies (Pizzagalli et al., 2008; Vrieze et al., 2012). Considered
alongside the current results, this line of evidence suggests that MDD
is associated with disruptions in multiple facets of reward processing—
but not necessarily within the same individuals. Indeed, basic research
indicates that the facets of reward processing are mediated by dissocia-
ble neural circuitry (Smith et al., 2011), suggesting that some cases of
MDD may be characterized primarily by a deficit in “liking,” others by
deficits in “wanting” or learning, and others by a combination of deficits
in multiple reward facets. The RDoC initiative provides an essential
framework for integrating the existing reward literature in MDD and
further exploring this possibility.
Aside from anhedonia, individuals with impaired mood reactivity
reported comparable symptoms of depression and anxiety. Thus, the
impairedmood reactivity subgroup was not more ill overall, and classi-
fying the current MDD sample based on mood reactivity provided
unique clinical information not apparent from the other symptommea-
sures. Whereas the DSM-defined subtypes of melancholic and atypical
MDD have been criticized for being largely unrelated to treatment re-
sponse (Bobo et al., 2011; Uher et al., 2011), a refinedmelancholic phe-
notype that is informed by neurobiological dysfunction may help to
inform treatment approaches by explaining clinical heterogeneity
that, at present, is not well understood. If the core role of mood reactiv-
ity status is validated in future research, this could be tested directly by
assessing the moderating role of mood reactivity status on treatment
outcome, separate from the DSM-defined subtypes. Conversely, it
Fig. 1. Feedback negativity (FN) elicited by monetary reward among control (top) and depressed groups (bottom). Headmaps represent the difference between loss and win outcomes
from 250 to 350 ms, where the FN was scored.
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would also be informative to test the extent to which mood reactivity
improves over the course of successful treatment—and whether this
maps onto normalization of reward-related neural activity.
Given comparable severity of the current depressive episode across
mood reactivity subgroups, it may be of interest to test for differences
in course of illness (Klein, 2008). There is some evidence that melan-
cholic MDD is more chronic than atypical MDD (Gili et al., 2012), a dis-
tinction which may become more pronounced as the phenotype is
further refined. By isolating the subgroup of MDD indicated here –
characterized by reward dysfunction and non-reactive mood – it may
be possible to more accurately understand and predict illness trajectory.
Indeed, preliminary evidence indicates that reduced FN amplitude
uniquely and prospectively predicts first-onset MDD in adolescence,
over and above the influence of family history, trait neuroticism, and
sub-threshold depressive symptoms (Bress et al., 2013a). Considered in
light of the currentfindings, reduced FNamplitude andVShypoactivation
may be relevant biomarkers for the course of illness specifically within
the subgroup of MDD with impaired mood reactivity. Furthermore,
while age of onset was unrelated to reward dysfunction here, other re-
search has linked an early age of onset to reduced left frontal neural activ-
ity during reward anticipation (Shankman et al., 2007). It will be valuable
for future work to evaluate how these different types of reward-related
neural activity change over time in MDD and whether such changes can
be used to better understand the course of illness, leading to more accu-
rate predictions of symptom onset, remission, and recurrence.
In contrast to the subgroup with non-reactive mood, those de-
pressed individuals with intact mood reactivity exhibited robust
reward-related neural activity across ERP and fMRI indices. This implies
that not all MDD is characterized by reward-related abnormalities; in
some individuals with MDD, reward processing may be unaffected. In
addition, FN amplitude and VS activation were directly correlated with
one another, a novel result in the MDD literature. This is consistent
with two previous studies in unselected samples (Becker et al., 2014;
Carlson et al., 2011), indicating convergence across electrophysiological
and hemodynamicmeasures of reward sensitivity. The FN appears to be
a highly effective tool for quantifying reward dysfunction in MDD and
clarifying the pathophysiology of melancholia, one which covaries di-
rectly with VS hypoactivation.
Fig. 2. Reduced reward-related neural activity among depressed individuals reporting impaired mood reactivity. (a) Feedback negativity (FN) among depressed individuals with intact
(top) and impaired (bottom) mood reactivity. (b) Group means and standard errors for FN amplitude. (c) Ventral striatal (VS) activation across the full sample (y = 10). (d) Group
means and standard errors for VS activation; controls include 12 non-depressed individuals not represented in part b. ⁎p b .05, ⁎⁎⁎p b .001.
Fig. 3. Scatterplot depicting the convergence across electrophysiological and hemodynam-
ic measures of reward-related neural activity within depressed group, as a function of
mood reactivity to positive events. ⁎pone-tailed b .05.
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One limitation of the current study is the relatively small sizes of the
MDD subgroups. Given that impaired mood reactivity was a fairly com-
mon phenomenonwithin theMDD sample (32.4%), it will be feasible to
extend thesefindings to larger clinical samples. Impairment inmood re-
activity was also not assessed among controls due to the assessment hi-
erarchy of the SCID; future work may clarify whether mood reactivity
similarly modulates reward-related neural activity within populations
that do not meet full diagnostic criteria for MDD, including healthy con-
trols as well as patients with subthreshold depressive symptoms. A sec-
ond limitation is that mood reactivity was assessed via a single item
from the SCID, which limits the reliability of this characteristic. We
view the current results as a necessary first step for refining the melan-
cholic phenotype and, if the link between impairedmood reactivity and
reward dysfunction is further substantiated by future research, it will be
important to develop a more thorough assessment tool for evaluating
this illness characteristic.
The current study focused on an unmedicated, female sample with
limited comorbidity, and it will be of interest to replicate these results
in more heterogeneous patient populations. By considering a wider
range of diagnostic and demographic categories, it will be possible to
test how neurobiological evidence of reward dysfunctionmay be utilized
to further improve our understanding of the boundaries between MDD
and other co-occurring disorders. In the same way that the present
study leveraged neural information of reward dysfunction to better un-
derstand individuals differences within MDD, it will be possible to apply
this same approach to more clinically complex populations with numer-
ous diagnoses, potentially utilizing evidence of reward dysfunction to
identify novel, distinct subgroups that are not capturedwithin the current
diagnostic framework. For example, itwould be of interest to consider the
interplay between depressive symptoms and other characteristics known
to impact reward processing, such as trait impulsivity and symptoms of
attention-deficit hyperactivity disorder (Plichta and Scheres, 2014).
Reward dysfunction is thought to play a central role in the patho-
physiology ofMDD, and the current study builds upon the existing liter-
ature by utilizing a multimodal neuroimaging approach. We found
converging evidence across methods, such that FN amplitude covaried
with VS activation. Further, both methods indicated the possibility of a
neurobiologically distinct subgroup of MDD characterized by impaired
mood reactivity to positive events, a core feature of melancholic MDD.
This subgroup exhibited significant reward dysfunction, whereas in
the subgroup with intact mood reactivity reward processing was unaf-
fected. The full, DSM-defined subtypes of melancholic and atypical
MDD, however, did notmap onto reward dysfunction. The existing sub-
types may be strengthened by integrating clinical definitions more
closely with evidence of biological dysfunction. Mood reactivity is a
key illness feature that may represent a fundamental divide between
distinct subgroups of MDD – indicated by reward dysfunction – and of-
fers a route for further refinement of the melancholic phenotype.
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